Healthcare provider profile · identity verified

Catherine Stober, MD

Internal Medicine · NASHVILLE, TN · NPI 1205923331

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	707	202
Levothyroxine Sodium	Levothyroxine Sodium	325	88
Fluticasone Propionate	Fluticasone Propionate	211	96
Lisinopril	Lisinopril	202	58
Losartan Potassium	Losartan Potassium	199	54
Amlodipine Besylate	Amlodipine Besylate	186	54
Omeprazole	Omeprazole	176	55
Hydrochlorothiazide	Hydrochlorothiazide	173	52
Simvastatin	Simvastatin	147	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	127	39
Metoprolol Succinate	Metoprolol Succinate	126	38
Famotidine	Famotidine	118	42
Rosuvastatin Calcium	Rosuvastatin Calcium	106	32
Escitalopram Oxalate	Escitalopram Oxalate	105	33
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	104	29
Gabapentin	Gabapentin	100	37
Trazodone Hcl	Trazodone Hcl	96	30
Sertraline Hcl	Sertraline Hcl	87	24
Metformin Hcl	Metformin Hcl	79	24
Alendronate Sodium	Alendronate Sodium	74	18
Allopurinol	Allopurinol	69	19
Synthroid	Levothyroxine Sodium	65	15
Azelastine Hcl	Azelastine Hcl	64	32
Valsartan	Valsartan	62	19
Pravastatin Sodium	Pravastatin Sodium	61	19
Bupropion Xl	Bupropion Hcl	60	18
Citalopram Hbr	Citalopram Hydrobromide	59	18
Duloxetine Hcl	Duloxetine Hcl	56	16
Pantoprazole Sodium	Pantoprazole Sodium	56	17
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	49	16
Carvedilol	Carvedilol	44	11
Eliquis	Apixaban	43	14
Mirtazapine	Mirtazapine	43	suppressed
Spironolactone	Spironolactone	42	15
Ozempic	Semaglutide	41	suppressed
Jardiance	Empagliflozin	39	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	38	24
Lovastatin	Lovastatin	36	11
Metformin Hcl Er	Metformin Hcl	33	14
Potassium Chloride	Potassium Chloride	29	suppressed
Valacyclovir	Valacyclovir Hcl	29	15
Ezetimibe	Ezetimibe	27	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Enalapril Maleate	Enalapril Maleate	25	suppressed
Nifedipine Er	Nifedipine	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Atenolol	Atenolol	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Irbesartan	Irbesartan	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	11
Meloxicam	Meloxicam	19	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	17
Ramipril	Ramipril	18	suppressed
Furosemide	Furosemide	17	suppressed
Verapamil Er	Verapamil Hcl	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Warfarin Sodium	Warfarin Sodium	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Estradiol	Estradiol	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Tizanidine Hcl	Tizanidine Hcl	14	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	13	suppressed
Memantine Hcl Er	Memantine Hcl	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Solifenacin Succinate	Solifenacin Succinate	12	suppressed
Arnuity Ellipta	Fluticasone Furoate	11	suppressed
Ipratropium Bromide	Ipratropium Bromide	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error